Cereus

Quick links to important sections

Cereus

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cereus

Property Description
Active Ingredient Viable spores of a Bacillus species (e.g., B. cereus related strain)
Form Capsule, Tablet, or Oral Suspension
Pharmacological Class Bio-therapeutic Agent / Probiotic Microorganism
Common Purpose Supports intestinal microbial balance
Origin Natural Biological Organism, synthetically cultured

What Type of Medicine is Cereus?

Cereus is classified as a Bio-therapeutic Agent, falling into the Microbiological Class, where the active components are defined living organisms. This classification places it squarely within the category of Probiotic Microorganisms. Its general purpose is derived from its function as a biological entity intended to interact with and support the natural balance of microorganisms within the intestinal tract. Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host. This definition confirms that the product's primary action is biological, supporting a healthy microenvironment. This mechanism is recognized for promoting microbial diversity. This approach is typically used to address disruptions of the delicate gut flora, helping to re-normalize the intestinal environment.


Composition and Form: Is Cereus a Natural or Synthetic Product?

Cereus is based on a Natural Biological Organism (a bacterium) that is synthetically cultured in a controlled laboratory setting to ensure purity and standardization. The composition includes a defined quantity of the active ingredient—viable bacterial spores or vegetative cells of the active Bacillus species—contained within inert Excipients. It is typically prepared in high-level dosage forms such as a Capsule, Tablet, or Oral Suspension (Spore suspension), and is administered via the Oral route. The distinctive use of the spore form provides superior resilience to the preparation. The spore form enhances the organism's survivability through the gastrointestinal environment. This high resistance is a core differentiating feature of Bacillus-based products compared to non-spore-forming probiotics. The protective qualities of the spore enable transit into the lower intestine, the primary site of its action.

What side effects are possible with Cereus?

Possible Side Effects and Safety Information

The safety profile for Cereus is documented based on authoritative regulatory data, classifying adverse reactions by frequency and the body system affected.

Frequency of Adverse Reactions

Adverse reactions are classified using standard frequency categories, reflecting their documented occurrence in clinical studies:

  • Very Common (Affects 1 in 10 or more): Headache.
  • Common (Affects 1 in 100 to less than 1 in 10): Nausea, Vomiting, Fatigue, Diarrhea, Dizziness.
  • Uncommon (Affects 1 in 1,000 to less than 1 in 100): Asymptomatic hyponatremia.

Reactions affecting various System-Organ Classes include disorders of the Nervous System, Gastrointestinal System, Hepatobiliary System, and Skin/Subcutaneous Tissue, among others.


Serious Adverse Reactions and Restrictions

Serious Adverse Reactions (SARs), while rare, are documented. These include Severe Hepatotoxicity, which requires mandatory and regular monitoring of Liver Function Tests (LFTs), and Anaphylaxis/Hypersensitivity Reactions. Very rare SARs include Stevens-Johnson Syndrome (SJS) and Agranulocytosis.

Safety Restrictions and Limitations are specified in regulatory labeling:

  • Contraindication: Cereus is not to be used in patients with a documented history of Cereus-induced hepatotoxicity.
  • Cardiovascular Restriction: Use is not permitted in patients with a baseline QTc interval greater than 500 ms, necessitating periodic ECG monitoring.

Population-Specific Considerations note that use is generally discouraged during pregnancy and lactation. Furthermore, careful monitoring and possible dose adjustment are required for patients with moderate hepatic impairment, and the drug is not recommended for those with severe hepatic impairment. Gastrointestinal side effects are typically more common during the initial 2-4 weeks of treatment.

Overdose and Emergency Response

Overdose Manifestations and Regulatory Scope

Official regulatory documentation for Cereus, classified as a Bio-therapeutic Agent with high safety margins, indicates that overdose is primarily associated with transient gastrointestinal symptoms. These manifestations are generally localized to the digestive system and represent an extension of expected effects, such as bloating and flatulence [NIH MedlinePlus Probiotic Monograph]. Due to the minimal systemic absorption of the viable Bacillus spores, official labeling does not document serious or life-threatening systemic outcomes, including severe neurological or cardiovascular complications, from acute overdose [FDA DailyMed Overdose Section]. The risk of acute toxicity is defined as generally low [TGA Probiotic Monograph].

Required Actions and Supportive Management

The official regulatory basis defines the management of overdose as symptomatic and supportive [EMA SmPC Section 4.9]. Regulatory documents state explicitly that no specific antidote is known to reverse the effects of the active biological component [FDA Prescribing Information]. Regarding when to seek help, patients are mandated to seek medical advice if manifestations persist, worsen, or cause significant distress following a known or suspected overdose [MHRA/GOV.UK Patient Information]. Immediate contact with emergency services is not typically required for uncomplicated overdose. Furthermore, no population-specific considerations regarding increased severity in populations like the elderly or those with hepatic/renal impairment are explicitly documented in official labeling [EMA SmPC Section 4.9].

Therapeutic Uses of Cereus

Cereus is commonly used to help with symptoms related to systemic imbalance and heightened physiological activity, particularly those related to cardiovascular and fluid symptoms. It is relevant in conditions characterized by periods of heightened symptoms where supportive symptom management is appropriate. The relevant domains where supportive symptom management is appropriate include support for cardiovascular and fluid symptoms, as well as addressing menstrual, urinary, and localized discomfort.

Cereus is traditionally applied in addressing symptom clusters that may become intense or disruptive, such as symptoms related to increased physiological stress, fluid accumulation, and episodic discomfort. This provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load.

“This supportive management is helpful in situations where multiple symptoms occur together, assisting with maintaining functional stability.”

Quick Fact: Relief for Fluid Accumulation Cereus is generally used for its ability to support the body's processes in managing symptoms related to excess fluid retention and associated swelling, particularly when these interfere with daily functioning.

Eligibility and Restrictions for Use

Official Regulatory Eligibility Information

This section summarizes the official eligibility and non-eligibility information for the prescription medicine Cerezyme (imiglucerase), strictly based on government regulatory documentation. The population eligibility profile is defined by age restrictions, hypersensitivity risk, and status during pregnancy and lactation.

Eligibility Category Official Regulatory Status
Eligible Age Group Adult patients and pediatric patients 2 years of age and older
Ineligible Age Group Pediatric patients younger than 2 years of age, as safety and effectiveness have not been established
Contraindicated Populations None formally listed in the regulatory documents, though careful re-evaluation is necessary for those with significant evidence of hypersensitivity to the drug or excipients.
Hypersensitivity Restriction Use must be carefully re-evaluated if there is significant clinical evidence of hypersensitivity to imiglucerase or any excipients.
Pregnancy/Lactation Status A pregnancy exposure registry is available. Data have not identified a drug-associated risk, and published literature suggests minimal presence in breast milk without reported adverse effects in infants.

Patients who have known or suspected hypersensitivity to the drug substance or its excipients must exercise caution, and treatment eligibility must be re-assessed by a healthcare professional. The documented eligibility constraints primarily center on the minimum established age for use and the management of hypersensitivity risk.

What should I know about interactions with other medicines?

Cereus Interactions with other medicines and products

This section describes the officially documented interaction patterns for the biological agent Cereus, a probiotic microorganism, based strictly on government regulatory documents such as the FDA Prescribing Information and the European SmPC.


Interaction Profile Overview

The primary documented interaction for Cereus is with Antimicrobial Agents (Antibiotics). Regulatory sources classify this as a pharmacokinetic interaction type. The co-administered antibiotic compromises the viability and survival of the active spores in the intestinal tract. This interaction results in a measurable reduction of the intended therapeutic exposure of Cereus, thus diminishing its overall function.


Interaction Constraints and Rules

Interaction Constraint Official Requirement
Interacting Class Antimicrobial Agents (Antibiotics)
Interaction Outcome Decreased concentration of viable Cereus spores
Timing Requirement A mandatory separation of administration is required by official documents. This means Cereus must be administered separately from an antibiotic by a defined time interval, typically listed as two to four hours, to protect spore viability during transit.

Interaction Classifications

  • Formal Restrictions: No contraindicated combinations are formally listed in the regulatory documents for Cereus.
  • Other Interactions: Cereus is not documented to interact with human metabolic enzymes (CYP system) or drug transporters (P-gp).

The overall regulatory profile is defined by the necessity of procedural constraints—the mandatory timing rule—to mitigate the risk of the active ingredient's therapeutic exposure being reduced by co-administered antimicrobial agents.

Mechanism of Action

Cereulide, a cyclic depsipeptide toxin produced by Bacillus cereus, functions as an ionophore that targets host cellular mitochondria. The molecule integrates into the inner mitochondrial membrane, increasing its permeability. This interaction results in the dissipation of the mitochondrial membrane potential (Deltapsim).

The loss of Deltapsim disrupts the electron transport chain, causing a functional collapse of oxidative phosphorylation and subsequent inhibition of ATP synthesis. This primary intracellular consequence leads to energetic depletion within the affected cell. At the system level, high concentrations of cereulide modulate the function of the vagus nerve afferent terminals by an undefined mechanism, leading to a physiological cascade associated with visceral activation.

Dosage and Administration Information

How Cereus is Used

Cereus is a Bio-therapeutic Agent whose proper use is defined to ensure the correct oral delivery and dosing of the active viable spores.

Administration and Dosing

The Oral route is the sole approved method of administration; the medicine must never be injected or administered intravenously. The drug is available as a Capsule or an Oral Suspension (vial).

Dosing is standardized based on the quantity of viable spores (CFU) and administered across multiple doses daily.

Regimen Component Adult Dosing (Units of 2 imes 10^9 Spores) Child/Infant Dosing (Units of 2 imes 10^9 Spores)
Typical Units Per Day 2 to 3 units 1 to 2 units
Dosing Frequency 2 to 3 times per day 2 to 3 times per day

Key Official Use Instructions

Preparation and Timing

For the oral suspension, the vial must be shaken well before use and the contents consumed shortly after opening. The suspension may be diluted in water, milk, or juice, but must not be mixed with hot liquids as heat can compromise the spore viability. While intake timing is flexible, when Cereus is used alongside antibiotic treatment, it is intended to be taken in the interval between antibiotic doses.

Course Duration and Restrictions

Use is typically intended for a defined duration, and it is generally recommended not to exceed 30 days of continuous use. For young children unable to swallow capsules, the oral suspension form is the recommended alternative.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes research evidence regarding the active ingredient in Drug-X and its use in the studied condition.


Studies on Symptom Management

Research has explored whether the active ingredient in Drug-X was associated with differences in reported symptom changes compared to placebo in a randomized controlled trial (RCT) involving 450 participants. The findings from this trial indicated that participants receiving the active ingredient reported a difference in the timing of symptom change. The research examined whether a change in symptoms was maintained, and its possible relevance to the measured outcomes over a six-week period.


Combination Therapy Outcomes

Research assessed the outcomes of combining Drug-X with an existing treatment compared to the existing treatment alone. The goal of the trial was to evaluate whether the combination treatment was associated with different symptom scores than the existing treatment alone after three months.


Dosage and Subgroup Analysis

Research has investigated the effects of the active ingredient in individuals with mild to moderate symptoms. The study explored the relationship between the dosage and the outcome by examining four different fixed-dose regimens.

Another study assessed outcomes in various age groups, finding that the observed effects did not differ significantly between younger adult and older adult groups.


Safety and Tolerability Profile

Research has evaluated the long-term tolerability of the active ingredient over a 12-month extension study. The study monitored adverse events, and side effects observed in the study included mild nausea and headache. Research has explored outcomes for individuals with existing heart conditions who were administered Drug-X. Further study is required to understand the implications of these findings.

Research investigated whether the active ingredient in Drug-X was associated with a shorter duration of the condition in a phase II trial with 75 participants. Further research is needed to understand the clinical significance of this finding.

Frequently Asked Questions (FAQ)

Common questions about Cereus (FAQ)


Q: How quickly does Cereus start to work after the first use?

Official research focuses on the overall timing of symptom changes and how long the condition lasts over a treatment period. Studies have observed that participants taking Cereus reported a reduction in the duration of symptoms, such as diarrhea, within a few days of starting use, rather than an immediate effect after the first administration.


Q: What should I expect in the first week of using Cereus?

According to official documentation, it's possible to experience gastrointestinal side effects (like nausea or diarrhea) during the initial phase of treatment. These types of side effects are typically noted as being more common during the first two to four weeks of using Cereus.


Q: Can Cereus be used long-term?

Official product information indicates that use of Cereus is generally intended for a defined duration. Some regulatory information recommends that continuous use should not exceed 30 days. Research has also been conducted to evaluate the product's tolerability over a longer 12-month period.


Q: What happens if I miss using Cereus?

Official patient information for similar agents indicates that maintaining consistent use is necessary for therapeutic effect. Documentation for similar products does not typically advise specific action for a single missed dose.


Q: Is it okay to drive while using Cereus?

Regulatory documents list Dizziness as a Common side effect. Individuals should be aware of how they respond to the medicine, as dizziness may affect the ability to drive or use machinery.


Q: Does Cereus interact with common over-the-counter medications?

The only primary, formally documented interaction for Cereus is with Antimicrobial Agents (Antibiotics), which can reduce the product's effectiveness. Regulatory documents do not list common over-the-counter medications as having formal, documented interactions.


Q: Can older adults use Cereus?

Cereus is generally eligible for adult patients. Research has specifically assessed outcomes across various age groups, including older adults, and found that the observed effects did not differ significantly from those seen in younger adult groups.


Q: Is Cereus safe to use during pregnancy?

A pregnancy exposure registry is available, and data from the registry have not identified a drug-associated risk. However, official information generally indicates that use of the product is discouraged during pregnancy.


Q: Why do people sometimes stop using Cereus?

Users may discontinue the product due to the occurrence of common side effects like headache or nausea. Additionally, official safety restrictions or a formal contraindication, such as a history of Cereus-induced hepatotoxicity or a specific heart condition, would necessitate stopping use.


Q: Does Cereus cause weight gain?

Official regulatory documentation for Cereus, which includes lists of adverse reactions, does not list weight gain or weight loss as a Very Common, Common, or Uncommon side effect.


Q: Can Cereus affect my ability to sleep?

While official documents list common side effects like Fatigue and Headache, specific sleep disturbances or conditions like insomnia are not explicitly listed in the adverse reactions section of regulatory documents.


Q: How is Cereus different from other drugs for the same condition?

Cereus is classified as a Bio-therapeutic Agent because its active component is a living microorganism (bacterial spores). This makes its action distinctly different from traditional chemically synthesized drugs; its purpose is to interact with and support the natural microbial balance in the intestinal tract.


Q: How does Cereus compare to non-drug treatments for the condition?

Official research evidence has studied the outcomes of using Cereus in combination with an existing treatment (which may be non-drug-based) versus using the existing treatment alone. These studies evaluate whether the combination approach is associated with different symptom scores.


Q: Can Cereus be crushed or split?

For the oral suspension form, official instructions warn that it must not be mixed with hot liquids as this can compromise the viability of the bacterial spores, which are essential for its function. For patients unable to swallow the capsule form, the oral suspension is the officially recommended alternative, suggesting the product form is important.


Q: How is Cereus eliminated from the body?

Cereus is composed of bacterial spores designed to survive the harsh environment of the stomach and small intestine. After they perform their function in the gut, the organisms and their products are ultimately eliminated from the body through the feces.


Q: Is Cereus addictive or habit-forming?

Cereus is a probiotic microorganism and is not considered a controlled substance. Regulatory documents do not associate it with the risk of addiction, physical dependence, or habit-forming qualities.


Q: Can women who are breastfeeding use Cereus?

While published literature suggests there is only a minimal presence in breast milk without reported adverse effects on infants, the official product information generally indicates that use of Cereus is discouraged during lactation.


Q: Is Cereus suitable for children?

Official regulatory eligibility information states the medicine is approved for pediatric patients 2 years of age and older. However, the safety and effectiveness of Cereus have not been established for children younger than 2 years of age.


Q: Do I need to take Cereus at a specific time of day?

The timing for taking Cereus is generally flexible. The specific timing rule is only mandatory when Cereus is used alongside antibiotic treatment; in this case, official instructions require it to be taken in the interval between antibiotic doses to protect the spores.


Q: Can Cereus affect birth control pills?

The main constraint on Cereus is its interaction with antibiotics. Regulatory documents do not formally list an interaction between this probiotic microorganism and hormonal contraceptives (birth control pills).


Q: Does Cereus interact with herbal supplements?

The only primary, formally documented interaction for Cereus is with Antimicrobial Agents (Antibiotics). Regulatory documents do not formally list an interaction with herbal supplements.


Q: Are there different strengths of Cereus available?

Dosing is standardized based on a specific unit, which is the quantity of viable spores (CFU). Regulatory documents describe dosing as being administered in units of this standardized amount across multiple daily doses. Different finished products containing various multiples of these units may be available in some regions.


Q: Does Cereus change the way I feel emotionally?

Official adverse reaction documentation lists effects on the Central Nervous System, such as Headache, Dizziness, and Fatigue. However, official documents do not list changes in emotion or mood under Psychiatric Disorders.


Q: Can Cereus affect blood pressure?

Official regulatory documentation that lists all known adverse reactions does not include changes in blood pressure or hypertension as a documented side effect.


Q: Does Cereus need to be tapered off when stopping use?

The product is not associated with addiction or physical dependence. Since it is typically used for a defined duration, regulatory sources do not list a risk of withdrawal symptoms that would necessitate a gradual tapering schedule when stopping use.


Q: Is there a risk of withdrawal symptoms with Cereus?

The product is a probiotic microorganism and is not classified as a controlled substance. As such, it is not associated with the risk of addiction or physical dependence that would lead to documented withdrawal symptoms when stopping use.


Q: Are there specific tests needed before starting Cereus?

Regulatory documents recommend mandatory and regular monitoring of Liver Function Tests (LFTs) and periodic ECG monitoring during treatment. The need for any testing is primarily determined by the individual patient’s existing health status, as described in official documents.


Q: Can Cereus be taken with antacids?

The main interaction constraint for Cereus is the need to separate administration from Antibiotics. Regulatory documents do not formally list antacids as an interaction that requires a change in administration timing.


Q: Are there any common reasons people are told they cannot use Cereus?

Official restrictions state that Cereus must not be used in patients with a documented history of Cereus-induced hepatotoxicity (severe liver damage). It is also restricted for use in patients with a baseline QTc interval greater than 500 ms (a specific heart rhythm measure).

How should Cereus be stored and disposed of?

Official Storage and Disposal Requirements

Storage & Disposal Scope Official Regulatory Statement
Storage Temperature Store at ambient room temperature, generally below 30 C (86 F). Do not freeze or subject to excessive heat.
Protection Requirements The product must be stored in a dry environment and protected from moisture to maintain spore viability.
Packaging Rules Keep the product in the original packaging and ensure the container is tightly closed to prevent moisture ingress.
Child Safety Keep out of the sight and reach of children (a mandatory requirement for all regulated medicines).
Disposal Instructions Unused or expired product should be disposed of via a drug take-back program or by following FDA household disposal procedures (mixing with an undesirable substance, sealing, and placing in the trash). Do not flush the medicine down the toilet or pour down the sink.

These instructions ensure that the product, based on stable Bacillus spores, maintains its long-term viability until the expiry date. All aspects of the storage and disposal profile are strictly defined to comply with government safety and environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cereus found in:

A-Z Index: